news roundup
According to ZRG Partners' Global Life Sciences Hiring Index, activity continues to grow, posting over 20% higher than a year ago.
|
advertisment
NORD’s Rare Diseases and Orphan Products Breakthrough Summit is the most meaningful multi-stakeholder event – historically featuring over 20 speakers from the FDA, participation from over 80 patient organizations and the Pharma/Biotech industry’s foremost experts in orphan product innovation, investment and commercialization.
The 2016 Summit is your opportunity to address the progress and innovations in rare disease diagnosis, treatment, engagement and access of orphan products.
 Learn more
|
WCCT Global and Medelis will help sponsors navigate the complexities of global oncology and immuno-oncology drug development.
|
advertisment
The State of Risk-based Monitoring (RBM)
Live Webinar: Tuesday, June 21, 2016 at 11 am – 12 pm EDT
 Register Free
|
The new model is designed to accelerate site start-up and patient recruitment in oncology clinical trials and only opens a site after a patient is identified.
|
|
|
advertisment
|
|
Subscribe
|
Stay connected with Applied Clinical Trials and sign up for your print or digital issues, as well as our enewsletters.
Subscription offers »
|
|
|
|
Regulatory
This article offers tips on how a CAPA program is a critical tool in response to an FDA Form 483 and can prevent a Warning Letter.
Prospectively designed registries and cohort studies are valuable, along with RCTs to guide clinical practice.
The standard allows sponsors to build applications that generate submissions for multiple, global clinical trial registries; specifically for WHO, EMA and ClinicalTrials.gov from a single file.
The European Medicines Agency departed from the tradition of tame complacency in its annual report published in mid-May, and featured non-official reflections from some distinctly non-official sources.
|
Blog Posts
Cancer programs fare worse than average, and a large proportion of Phase III studies fail to support market applications.
One use allows investigators to use a single identity that can be recognized across business, government and academic entities.
Take our survey today!
|
|
|
|
advertisment
BIOVISUALIZATION
Effective Mining and Interpretation of Laboratory Results Data
On Demand
 Read more
|
Articles
Broad consumer use of wearable devices is building familiarity and will facilitate the implementation of similar medical grade devices in clinical studies.
This article discusses which emergent technologies have the potential to further disrupt the clinical trial process.
|
|
|
|
|
|
Read the digital edition of Applied Clinical Trials
Click here to sign up or renew your subscription
|
|
|
|
|
